Our Statement on Recent Talc Verdict
Have Questions About Participating in a COVID-19 Vaccine Clinical Trial? A Doctor Overseeing a Study Helps Answer ThemDid you like reading this story? Click the heart to show your love.
Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19Did you enjoy reading this story? Click the heart.
Did you like taking this quiz? Click the heart to show your love.
"We deeply sympathize with the women and families impacted by ovarian cancer. We will begin the appeals process following today’s verdict and believe a jury decision in our favor in St. Louis in March and the dismissal of two cases in New Jersey in September 2016 by a state court judge who ruled that plaintiffs’ scientific experts could not adequately support their theories that talcum powder causes ovarian cancer, further highlight the lack of credible scientific evidence behind plaintiffs’ allegations. We are preparing for additional trials this year and we will continue to defend the safety of Johnson’s Baby Powder." - Carol Goodrich, Global Media Relations, Johnson & Johnson Consumer, Inc.
For more information, please also see: 5 Important Facts About the Safety of Talc